SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Suma who wrote (22139)9/24/2005 11:36:37 AM
From: gcrispin  Read Replies (2) of 78627
 
<PFE is going to certainly face law suits too.>

Suma,

I don't know on what basis you have come to that conclusion. I think the decline in PFE is a result of expiring patents and the possible loss of the Lipitor patent. Also, much new money is going to biotech (ala DNA) rather than the traditional pharma companies. That said, PFE has some interesting prospects, including drug candidates from their acquisition of Esperion. I think the HDL market could greatly enhance its Lipitor franchise.

I only own PFE through multi-year long-term holdings in Vanguard Health. I might consider buying it at the end of this year.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News